Most-favoured-nation drug pricing · Senate · Apr 23, 2026 · 49–49
Took Pharma and health care money, voted Pharma and health care's way: 52%. Took none: 0%.
52%
of 92 funded members voted its way
vs
0%
of 5 unfunded members did
$192K
average from the industry, members who voted its way
$171K
average from the industry, members who defied it
79
clients paid lobbyists to work this bill, $245M in the quarters they named it
Paid, and voted with the industry
- Roger Marshall$492K
- Thom Tillis$454K
- Jon Husted$423K
- Tim Scott$416K
- Mitch McConnell$411K
Paid, and defied it
- Catherine Cortez Masto$841K
- Lisa Blunt Rochester$655K
- John Fetterman$580K
- Susan Collins$529K
- Ron Wyden$419K
A 2026 budget motion to peg US drug prices to what other rich countries pay. Tied 49–49, so it failed. Pharma and health care wanted nay. "Funded" means $10K+ from the industry across every run since 2020.
The full detail →